These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1409866)

  • 21. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment.
    Nagaoka S; Iwamoto N; Arai H
    Biol Psychiatry; 1997 Apr; 41(8):857-64. PubMed ID: 9099412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy.
    Wei FC; Jann MW; Lin HN; Piao-Chien C; Chang WH
    J Clin Psychiatry; 1996 Jul; 57(7):298-302. PubMed ID: 8666571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bromperidol maintenance in schizophrenia.
    McEvoy JP; Wilson WH; Ban TA; Brannen JO; Berney S
    Pharmacopsychiatria; 1982 May; 15(3):95-6. PubMed ID: 7100263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuroleptic radioreceptor activity and clinical outcome in schizophrenia.
    Contreras S; Alexander H; Faber R; Bowden C
    J Clin Psychopharmacol; 1987 Apr; 7(2):95-8. PubMed ID: 3584527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
    Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
    Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of therapeutic response to haloperidol in acute schizophrenia.
    McEvoy JP; Schooler NR; Wilson WH
    Psychopharmacol Bull; 1991; 27(2):97-101. PubMed ID: 1924667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disposition of haloperidol pyridinium and reduced haloperidol pyridinium in schizophrenic patients: no relationship with clinical variables during short-term treatment.
    Ulrich S; Neuhof S; Braun V; Danos P; Pester U; Hoy L
    J Clin Psychopharmacol; 2000 Apr; 20(2):210-9. PubMed ID: 10770460
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation of clinical response (PANSS) and plasma levels of haloperidol and reduced haloperidol in schizophrenia.
    Leroux JM; Elia E; Jacquet M; Pommery J; Levron JC; Bouhours P; Erb F; Sechter D
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Mar; 18(2):347-53. PubMed ID: 8208983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of haloperidol levels between saliva and plasma of acutely ill schizophrenic patients.
    Jain T; Bhandari A; Ram V; Sharma S; Parakh M; Parakh MC
    Clin Biochem; 2011 Jun; 44(8-9):675-80. PubMed ID: 21458435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Megabore capillary gas-liquid chromatographic method with nitrogen-phosphorus selective detection for the assay of haloperidol and reduced haloperidol in serum: results of therapeutic drug-monitoring during acute therapy of eight schizophrenics.
    Ulrich S; Meyer FP; Neuhof S; Knorr W
    J Chromatogr B Biomed Appl; 1995 Jan; 663(2):289-96. PubMed ID: 7735476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The relationship between haloperidol blood levels and clinical responses.
    Itoh H; Yagi G; Fujii Y; Iwamura K; Ichikawa K
    Prog Neuropsychopharmacol Biol Psychiatry; 1984; 8(2):285-92. PubMed ID: 6539935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v radioreceptor plasma level assays.
    Smith RC; Baumgartner R; Misra CH; Mauldin M; Shvartsburd A; Ho BT; DeJohn C
    Arch Gen Psychiatry; 1984 Nov; 41(11):1044-9. PubMed ID: 6497566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantification of reduced haloperidol and haloperidol by radioimmunoassay.
    Browning JL; Harrington CA; Davis CM
    J Immunoassay; 1985; 6(1-2):45-66. PubMed ID: 4019788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical implications of determination of plasma haloperidol levels.
    Santos JL; Cabranes JA; Almoguera I; Ramos JA; Vazquez C; Angeles F
    Acta Psychiatr Scand; 1989 Apr; 79(4):348-54. PubMed ID: 2735205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma drug level and clinical response.
    Cooper TB; Volavka J; Czobor P
    J Clin Psychopharmacol; 1992 Apr; 12(2):134-6. PubMed ID: 1573036
    [No Abstract]   [Full Text] [Related]  

  • 36. Determination of haloperidol and reduced haloperidol in human serum by liquid chromatography after fluorescence labeling based on the Suzuki coupling reaction.
    Kishikawa N; Hamachi C; Imamura Y; Ohba Y; Nakashima K; Tagawa Y; Kuroda N
    Anal Bioanal Chem; 2006 Oct; 386(3):719-24. PubMed ID: 16957915
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low plasma reduced haloperidol/haloperidol ratios in Chinese patients.
    Chang WH; Chen TY; Lee CF; Hu WH; Yeh EK
    Biol Psychiatry; 1987 Nov; 22(11):1406-8. PubMed ID: 3663790
    [No Abstract]   [Full Text] [Related]  

  • 38. Plasma haloperidol levels and clinical response.
    Smith RC
    Arch Gen Psychiatry; 1987 Dec; 44(12):1110-2. PubMed ID: 3689100
    [No Abstract]   [Full Text] [Related]  

  • 39. Serum haloperidol levels and clinical response in chronic, treatment-resistant schizophrenic patients.
    Browne FW; Cooper SJ; Wilson R; King DJ
    J Psychopharmacol; 1988 Jan; 2(2):94-103. PubMed ID: 22155843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Haloperidol blood levels during dosage reduction in chronic schizophrenic patients.
    Goldman Z; Ebstein RP; Lerer B; Zohar J; Hermoni M; Belmaker RH
    Neuropsychobiology; 1981; 7(6):281-4. PubMed ID: 7312145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.